在收入低于预期和股价上涨的情况下,Insmed董事出售了16.65亿美元的股票。 Insmed directors sold $16.65M in stock amid lower-than-expected earnings and a rising share price.

2025年11月14日和17日,Insmed董事Elizabeth Anderson和Leo Lee出售公司股票共计1 665万美元,李的总交易额达1 469万美元。 On November 14 and 17, 2025, Insmed directors Elizabeth Anderson and Leo Lee sold a combined $16.65 million in company stock, with Lee's transaction totaling $14.69 million. 向证交会报告了销售情况,大大减少了他们的股权。 The sales were reported to the SEC, reducing their ownership stakes significantly. 据Insmed报告,第三季度收入为每股1.75美元损失,低于估计数,尽管收入逐年增加52.4%,达1.4234亿美元。 Insmed reported third-quarter earnings of a $1.75 loss per share, below estimates, though revenue rose 52.4% year-over-year to $142.34 million. 11月18日的股票交易额为201.62美元,增加4.22美元,比平均数额低。 The stock traded at $201.62 on November 18, up $4.22, with lower-than-average volume. 该公司专注于罕见疾病,市场上限为430亿美元,P/E比率为负数。 The company, focused on rare diseases, has a $43 billion market cap and a negative P/E ratio. 分析师维持“机动购买”共识,平均目标为173.29美元。 Analysts maintain a "Moderate Buy" consensus with a $173.29 average target. Artisan Partners在本季度增加了49%的股份。 Artisan Partners increased its stake by 49% in the quarter.